282 related articles for article (PubMed ID: 17536870)
21. Ease of use of tobramycin inhalation powder compared with nebulized tobramycin and colistimethate sodium: a crossover study in cystic fibrosis patients with pulmonary Pseudomonas aeruginosa infection.
Greenwood J; Schwarz C; Sommerwerck U; Nash EF; Tamm M; Cao W; Mastoridis P; Debonnett L; Hamed K
Ther Adv Respir Dis; 2017 Jul; 11(7):249-260. PubMed ID: 28614995
[TBL] [Abstract][Full Text] [Related]
22. [TOBI Podhaler for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis patients].
Pierart F
Rev Med Liege; 2013 Sep; 68(9):486-8. PubMed ID: 24180205
[TBL] [Abstract][Full Text] [Related]
23. Tobramycin inhalation powder (Tobi Podhaler) for cystic fibrosis.
Med Lett Drugs Ther; 2013 Jun; 55(1419):51-2. PubMed ID: 23797798
[No Abstract] [Full Text] [Related]
24. In vitro aerodynamic characterization of the dose emitted during nebulization of tobramycin high strength solution by novel and jet nebulizer delivery systems.
Mashat M; Clark BJ; Assi KH; Chrystyn H
Pulm Pharmacol Ther; 2016 Apr; 37():37-42. PubMed ID: 26747025
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics and safety of an 8 week continuous treatment with once-daily versus twice-daily inhalation of tobramycin in cystic fibrosis patients.
van Koningsbruggen-Rietschel S; Heuer HE; Merkel N; Posselt HG; Staab D; Sieder C; Ziegler J; Krippner F; Rietschel E
J Antimicrob Chemother; 2016 Mar; 71(3):711-7. PubMed ID: 26626719
[TBL] [Abstract][Full Text] [Related]
26. Physicochemical compatibility and stability of nebulizable drug admixtures containing Dornase alfa and tobramycin.
Klemmer A; Krämer I; Kamin W
Pulm Pharmacol Ther; 2014 Jun; 28(1):53-59. PubMed ID: 24035821
[TBL] [Abstract][Full Text] [Related]
27. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial.
Konstan MW; Flume PA; Kappler M; Chiron R; Higgins M; Brockhaus F; Zhang J; Angyalosi G; He E; Geller DE
J Cyst Fibros; 2011 Jan; 10(1):54-61. PubMed ID: 21075062
[TBL] [Abstract][Full Text] [Related]
28. Population Pharmacokinetics of Tobramycin Inhalation Solution in Pediatric Patients With Cystic Fibrosis.
Wang X; Koehne-Voss S; Anumolu SS; Yu J
J Pharm Sci; 2017 Nov; 106(11):3402-3409. PubMed ID: 28634121
[TBL] [Abstract][Full Text] [Related]
29. Higher tobramycin concentration and vibrating mesh technology can shorten antibiotic treatment time in cystic fibrosis.
Coates AL; Denk O; Leung K; Ribeiro N; Chan J; Green M; Martin S; Charron M; Edwardes M; Keller M
Pediatr Pulmonol; 2011 Apr; 46(4):401-8. PubMed ID: 21438171
[TBL] [Abstract][Full Text] [Related]
30. Technical report: precautions regarding the use of aerosolized antibiotics. Committee on Infectious Diseases and Committee on Drugs.
Prober CG; Walson PD; Jones J
Pediatrics; 2000 Dec; 106(6):E89. PubMed ID: 11099632
[TBL] [Abstract][Full Text] [Related]
31. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group.
Ramsey BW; Pepe MS; Quan JM; Otto KL; Montgomery AB; Williams-Warren J; Vasiljev-K M; Borowitz D; Bowman CM; Marshall BC; Marshall S; Smith AL
N Engl J Med; 1999 Jan; 340(1):23-30. PubMed ID: 9878641
[TBL] [Abstract][Full Text] [Related]
32. [Use of inhaled tobramycin in patients with cystic fibrosis].
Chermenskiĭ AG; Gembitskaia TE
Ter Arkh; 2010; 82(8):76-8. PubMed ID: 20873251
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of aerosolized tobramycin in cystic fibrosis.
Pai VB; Nahata MC
Pediatr Pulmonol; 2001 Oct; 32(4):314-27. PubMed ID: 11568993
[TBL] [Abstract][Full Text] [Related]
34. TOBI: reducing the impact of pseudomonal infection.
Govan J
Hosp Med; 2002 Jul; 63(7):421-5. PubMed ID: 12187603
[TBL] [Abstract][Full Text] [Related]
35. TOBI Podhaler for cystic fibrosis patients with Pseudomonas aeruginosa.
Farinde A
Nurse Pract; 2015 Jul; 40(7):16-7. PubMed ID: 26080292
[No Abstract] [Full Text] [Related]
36. Tobramycin Inhalation Powder™: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis.
Parkins MD; Elborn JS
Expert Rev Respir Med; 2011 Oct; 5(5):609-22. PubMed ID: 21955231
[TBL] [Abstract][Full Text] [Related]
37. Savings in direct medical costs from the use of tobramycin solution for inhalation in patients with cystic fibrosis.
LeLorier J; Perreault S; Birnbaum H; Greenberg P; Sheehy O
Clin Ther; 2000 Jan; 22(1):140-51. PubMed ID: 10688397
[TBL] [Abstract][Full Text] [Related]
38. A comparison of peak sputum tobramycin concentration in patients with cystic fibrosis using jet and ultrasonic nebulizer systems. Aerosolized Tobramycin Study Group.
Eisenberg J; Pepe M; Williams-Warren J; Vasiliev M; Montgomery AB; Smith AL; Ramsey BW
Chest; 1997 Apr; 111(4):955-62. PubMed ID: 9106575
[TBL] [Abstract][Full Text] [Related]
39. Eradication of
Akkerman-Nijland AM; Yousofi M; Rottier BL; Van der Vaart H; Burgerhof JGM; Frijlink HW; Touw DJ; Koppelman GH; Akkerman OW
Ther Adv Respir Dis; 2020; 14():1753466620905279. PubMed ID: 32046620
[TBL] [Abstract][Full Text] [Related]
40. Administration of aerosolized antibiotics in cystic fibrosis patients.
Moss RB
Chest; 2001 Sep; 120(3 Suppl):107S-113S. PubMed ID: 11555564
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
